RXSTHealthcare · Medical DevicesThe 10 Wall Street analysts covering RxSight, Inc. hold a median 12-month price target of $6.75 — +8.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores RxSight, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (72): Analysts have, on balance, been raising their forecasts.
Momentum (20): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RXST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +8.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Stifel | Maintains | Hold | $8.00 → $7.00 |
| 6 Aug 2026 | UBS | Maintains | Neutral | $5.50 → $6.30 |
| 28 July 2026 | UBS | Assumes | Neutral | $9.00 → $5.50 |
| 7 July 2026 | B of A Securities | Maintains | Underperform | — |
| 7 July 2026 | B of A Securities | Maintains | Underperform | $8.00 → $6.50 |
| 7 July 2026 | Needham | Reiterates | Buy | $11 |
| 7 July 2026 | Needham | Reiterates | Buy | — |
| 7 May 2026 | Needham | Maintains | Buy | — |
| 7 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Mar 2026 | Stifel | Maintains | Hold | — |
| 26 Feb 2026 | Needham | Reiterates | Buy | — |
| 26 Feb 2026 | Piper Sandler | Maintains | Neutral | — |
| 26 Feb 2026 | UBS | Maintains | Neutral | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Neutral | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 6 Nov 2025 | Needham | Maintains | Buy | — |
| 6 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 Aug 2025 | Needham | Maintains | Buy | — |
| 8 Aug 2025 | Stifel | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RXST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 53% of US stocks
Cheaper than 74% of US stocks
Cheaper than 67% of US stocks
Higher than 28% of US stocks
Higher than 36% of US stocks
Higher than 88% of US stocks
Higher than 18% of US stocks
Higher than 12% of US stocks
Higher than 32% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own RxSight, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
RxSight, Inc. (RXST) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item presents the company's earnings call discussion material.
Why it matters — A RxSight watcher would review the transcript for management commentary on its Q2 2026 results and outlook.
RxSight reported second-quarter revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon. Management withdrew full-year 2026 financial guidance as new CEO Aziz Mottiwala conducts a broader assessment of the business.
Why it matters — A RxSight watcher would care because the withdrawal of full-year guidance and the new CEO's business review signal potential strategic changes and reduced forward visibility for the company.
RxSight reported a Q2 loss of $0.11 per share, narrower than the Zacks Consensus Estimate of a $0.21 loss but wider than the $0.08 loss posted in the year-ago quarter. The company also beat revenue estimates for the period.
Why it matters — A narrower-than-expected quarterly loss and a revenue beat indicate RxSight's results came in ahead of what analysts had anticipated.
RxSight, Inc. reported its financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. The announcement was made on August 5, 2026, via GlobeNewswire.
Why it matters — RXST watchers would care because the company disclosed its latest quarterly financial performance and revised guidance on its full-year 2026 outlook.
Zacks Investment Research previewed RxSight's Q2 earnings, noting the company lacks the key ingredients for a likely earnings beat and expects earnings to decline.
Why it matters — RXST watchers would care because the preview suggests the upcoming quarterly results may fall short of expectations.
The 10 Wall Street analysts covering RxSight, Inc. have a median 12-month price target of $6.75, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering RxSight, Inc., 1 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks RxSight, Inc. 49 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, RxSight, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +8.0% from the last close, and Ticker Nerd's factor model ranks RxSight, Inc. 49 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering RxSight, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.
RxSight, Inc. returned -28.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
RxSight Inc. is a healthcare company specializing in the development and commercialization of innovative ophthalmic implantable devices.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript". RxSight, Inc. (RXST) published the transcript of its Q2 2026 earnings call, as covered by Seeking Alpha. The item presents the company's earnings call discussion material.
RxSight Inc. is a healthcare company specializing in the development and commercialization of innovative ophthalmic implantable devices. Its primary product line includes light adjustable lenses, which allow patients to adjust and customize their vision post-cataract surgery, enhancing visual outcomes. This ability to fine-tune vision is achieved using proprietary technology that utilizes ultraviolet light to adjust the lens power after surgical implantation and healing. RxSight Inc. plays a significant role in the ophthalmology sector, particularly in refractive cataract surgery, offering an advanced solution that addresses limitations of traditional intraocular lenses. With a focus on improving patient satisfaction and enhancing the precision of vision correction, RxSight Inc. is pivotal in advancing eye care solutions and is a key player in medical innovation within the healthcare market landscape.
CEO Mr. Aziz Mottiwala M.B.A. · 461 employees · United States · https://rxsight.com